Cargando…

Treatment of Low-Blast Count AML using Hypomethylating Agents

In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS). However, this AML subtype, defined as low-blast count AML (LBC-AML,...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Bellis, Eleonora, Fianchi, Luana, Buccisano, Francesco, Criscuolo, Marianna, Maurillo, Luca, Cicconi, Laura, Brescini, Mattia, Del Principe, Maria Ilaria, Di Veroli, Ambra, Venditti, Adriano, Amadori, Sergio, Arcese, William, Lo-Coco, Francesco, Voso, Maria Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499495/ https://www.ncbi.nlm.nih.gov/pubmed/28698788 http://dx.doi.org/10.4084/MJHID.2017.045

Ejemplares similares

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
por: Sarlo, Chiara, et al.
Publicado: (2013)

Treatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts
por: Maurillo, Luca, et al.
Publicado: (2013)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy
por: Del Principe, Maria Ilaria, et al.
Publicado: (2014)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
por: Gurnari, Carmelo, et al.
Publicado: (2022)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Fever of Unknown Origin and Multidrug Resistant Organism Colonization in AML Patients
por: Guarnera, Luca, et al.
Publicado: (2023)

Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
por: Palmieri, Raffaele, et al.
Publicado: (2020)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Clonal evolution in therapy-related neoplasms
por: Fabiani, Emiliano, et al.
Publicado: (2017)

Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma
por: Pasqualone, Gianmario, et al.
Publicado: (2022)

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19
por: Cristiano, Antonio, et al.
Publicado: (2022)

NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma
por: Coppola, Andrea, et al.
Publicado: (2015)

Recurrence of a t(8;21)-Positive Acute Myeloid Leukemia in the Form of a Granulocytic Sarcoma Involving Cranial Bones: A Diagnostic and Therapeutic Challenge
por: Di Veroli, Ambra, et al.
Publicado: (2013)

Progress and criticalities in the management of acute promyelocytic leukemia
por: Lo-Coco, Francesco, et al.
Publicado: (2017)

Prognostic factors and treatment of secondary leukemia
por: Voso, Maria Teresa, et al.
Publicado: (2018)

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
por: Buccisano, Francesco, et al.
Publicado: (2021)

Similarities and Differences Between Therapy-Related and Elderly Acute Myeloid Leukemia
por: D’Alò, Francesco, et al.
Publicado: (2011)

Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
por: Molica, Matteo, et al.
Publicado: (2022)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Therapy-related Myeloid Neoplasms: Considerations for Patients’ Clinical Evaluation
por: Palmieri, Raffaele, et al.
Publicado: (2023)

Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage
por: Arriga, Roberto, et al.
Publicado: (2015)

Therapy-related myeloid neoplasms: clinical perspectives
por: Fianchi, Luana, et al.
Publicado: (2018)

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
por: Caratelli, Sara, et al.
Publicado: (2017)

Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience
por: Cefalo, Mariagiovanna, et al.
Publicado: (2019)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
por: Faraoni, Isabella, et al.
Publicado: (2019)

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts
por: Greve, Gabriele, et al.
Publicado: (2023)

P478: MOLECULAR CHARACTERIZATION OF EXTRAMEDULLARY LOCALIZATIONS IN ACUTE MYELOID LEUKEMIA (AML)
por: Silvestrini, Giorgia, et al.
Publicado: (2023)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature
por: Forghieri, Fabio, et al.
Publicado: (2016)

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
por: Campagna, Alessia, et al.
Publicado: (2022)

5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.
por: Greco, M., et al.
Publicado: (2011)

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry
por: Mayer, Flavia, et al.
Publicado: (2017)

Mutational profile of ZBTB16‐RARA‐positive acute myeloid leukemia
por: Fabiani, Emiliano, et al.
Publicado: (2021)

Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile
por: Guarnera, Luca, et al.
Publicado: (2023)

Prof. Franco Mandelli Leukaemia Visionary. May 12, 1931– July 15, 2018
por: Amadori, Sergio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v5iimvqkkrcds0hhser5lgtb4j